- Home
- EDSA vs CLDI Comparison
EDSA vs CLDI Comparison
Compare EDSA & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- CLDI
- Stock Information
- Founded
- EDSA 2015
- CLDI 2014
- Country
- EDSA Canada
- CLDI United States
- Employees
- EDSA N/A
- CLDI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDSA Health Care
- CLDI Health Care
- Exchange
- EDSA Nasdaq
- CLDI Nasdaq
- Market Cap
- EDSA 13.5M
- CLDI 8.3M
- IPO Year
- EDSA N/A
- CLDI N/A
- Fundamental
- Price
- EDSA $4.10
- CLDI $1.19
- Analyst Decision
- EDSA Strong Buy
- CLDI Strong Buy
- Analyst Count
- EDSA 1
- CLDI 3
- Target Price
- EDSA $21.00
- CLDI $16.67
- AVG Volume (30 Days)
- EDSA 14.3K
- CLDI 76.2K
- Earning Date
- EDSA 12-13-2024
- CLDI 11-12-2024
- Dividend Yield
- EDSA N/A
- CLDI N/A
- EPS Growth
- EDSA N/A
- CLDI N/A
- EPS
- EDSA N/A
- CLDI N/A
- Revenue
- EDSA N/A
- CLDI N/A
- Revenue This Year
- EDSA N/A
- CLDI N/A
- Revenue Next Year
- EDSA N/A
- CLDI N/A
- P/E Ratio
- EDSA N/A
- CLDI N/A
- Revenue Growth
- EDSA N/A
- CLDI N/A
- 52 Week Low
- EDSA $2.50
- CLDI $0.96
- 52 Week High
- EDSA $6.46
- CLDI $30.60
- Technical
- Relative Strength Index (RSI)
- EDSA 42.79
- CLDI 55.36
- Support Level
- EDSA $4.20
- CLDI $0.96
- Resistance Level
- EDSA $4.36
- CLDI $1.22
- Average True Range (ATR)
- EDSA 0.28
- CLDI 0.08
- MACD
- EDSA -0.02
- CLDI 0.02
- Stochastic Oscillator
- EDSA 10.00
- CLDI 85.19
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.